ProKidney Corp.
NASDAQ: PROK0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Capital Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Bruce Culleton
- Employees
- 204
- Headquarters
- Winston-Salem, United States
- IPO year
- 2021
- Market cap
- $595.2M
- Website
- https://www.prokidney.com
Loading PROK…
Loading profile data…Frequently asked questions about PROK
What does ProKidney Corp. (PROK) do?
ProKidney Corp. is a biotechnology firm currently in the clinical trial phase, specializing in the development of innovative cell-based treatments. Their flagship product is Renal Autologous Cell Therapy (RAC-T), a unique cellular admixture derived from a patient's own cells. RAC-T is undergoing significant clinical evaluation; it is concurrentl...
Where does PROK trade?
ProKidney Corp. (PROK) trades on the NASDAQ Capital Market.
What sector is PROK in?
ProKidney Corp. (PROK) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of ProKidney Corp.?
Bruce Culleton is the chief executive officer of ProKidney Corp. (PROK).
Where is ProKidney Corp. headquartered?
ProKidney Corp. is headquartered in United States.
Does PROK pay a dividend?
ProKidney Corp. (PROK) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did PROK go public?
ProKidney Corp. (PROK) completed its initial public offering in 2021.